Sensitivity to Cisplatin in Head and Neck Cancer Cells Is Significantly Affected by Patient-Derived Cancer-Associated Fibroblasts.
Aged
Aged, 80 and over
Antineoplastic Agents
/ pharmacology
Cancer-Associated Fibroblasts
/ drug effects
Cell Line, Tumor
Cisplatin
/ pharmacology
Coculture Techniques
Drug Resistance, Neoplasm
/ drug effects
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Head and Neck Neoplasms
/ metabolism
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
/ metabolism
Paracrine Communication
/ drug effects
Squamous Cell Carcinoma of Head and Neck
/ metabolism
Tumor Stem Cell Assay
cancer recurrence
cancer-associated fibroblasts
cisplatin
coculture
head and neck cancer
patient-derived cell cultures
treatment resistance
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
15 Feb 2021
15 Feb 2021
Historique:
received:
06
01
2021
revised:
29
01
2021
accepted:
06
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
24
4
2021
Statut:
epublish
Résumé
Cancer-associated fibroblasts (CAFs) are one of the most abundant and critical components of the tumor stroma. CAFs can impact many important steps of cancerogenesis and may also influence treatment resistance. Some of these effects need the direct contact of CAFs and cancer cells, while some involve paracrine signals. In this study, we investigated the ability of head and neck squamous cell carcinomas (HNSCC) patient-derived CAFs to promote or inhibit the colony-forming ability of HNSCC cells. The effect of cisplatin on this promoting or inhibiting influence was also studied. The subsequent analysis focused on changes in the expression of genes associated with cancer progression. We found that cisplatin response in model HNSCC cancer cells was modified by coculture with CAFs, was CAF-specific, and different patient-derived CAFs had a different "sensitizing ratio". Increased expression of
Identifiants
pubmed: 33671869
pii: ijms22041912
doi: 10.3390/ijms22041912
pmc: PMC7918851
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Grantová Agentura České Republiky
ID : 18-03978S
Organisme : Agentura Pro Zdravotnický Výzkum České Republiky
ID : NV18-08-00229
Références
J Natl Cancer Inst. 2016 Sep 15;109(1):
pubmed: 27634934
Semin Cancer Biol. 2004 Jun;14(3):149-54
pubmed: 15246049
BMC Cancer. 2019 May 22;19(1):485
pubmed: 31118072
Sci Rep. 2016 Dec 06;6:38408
pubmed: 27922075
Cancer Biother Radiopharm. 2010 Feb;25(1):75-80
pubmed: 20187799
Anticancer Res. 2010 Feb;30(2):455-62
pubmed: 20332454
Mol Cell Biol. 1991 Jun;11(6):3125-31
pubmed: 2038321
Oncol Rep. 2016 Jun;35(6):3265-74
pubmed: 27108527
Nat Rev Clin Oncol. 2016 Feb;13(2):66
pubmed: 26718111
JAMA Otolaryngol Head Neck Surg. 2015 Jun;141(6):543-9
pubmed: 25855885
Nat Rev Cancer. 2009 Sep;9(9):665-74
pubmed: 19693095
Br J Cancer. 2014 Aug 12;111(4):799-806
pubmed: 25032734
Autophagy. 2020 Jul;16(7):1296-1313
pubmed: 31612776
Cell Death Dis. 2018 Jul 9;9(7):759
pubmed: 29988148
Sci Rep. 2017 Jul 25;7(1):6478
pubmed: 28744021
Int J Cancer. 1991 Sep 30;49(3):431-5
pubmed: 1655661
Int J Mol Sci. 2015 Oct 12;16(10):24094-110
pubmed: 26473842
Biomed Pharmacother. 2018 Jan;97:1341-1348
pubmed: 29156523
Br J Cancer. 2003 Nov 17;89(10):1940-9
pubmed: 14612907
Trends Genet. 2013 Oct;29(10):569-74
pubmed: 23810203
Int J Mol Sci. 2012;13(8):9545-71
pubmed: 22949815
PLoS Comput Biol. 2017 Nov 3;13(11):e1005752
pubmed: 29099853
J Hematol Oncol. 2019 Aug 28;12(1):86
pubmed: 31462327